May 7, 2026 07:03AM
May 7, 2026 06:59AM
Feb 26, 2026 07:46AM
Feb 26, 2026 06:58AM
Nov 6, 2025 08:14AM
Nov 6, 2025 06:59AM
Aug 7, 2025 08:35AM Aclaris Therapeutics (ACRS) Tops Q2 EPS by 1c
Aug 7, 2025 06:59AM
May 8, 2025 04:31PM
May 8, 2025 06:50AM
Feb 27, 2025 07:02AM
Feb 27, 2025 06:59AM
Nov 6, 2024 07:00AM
Aug 7, 2024 07:00AM Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
May 7, 2024 04:01PM
Apr 30, 2024 07:00AM
Feb 27, 2024 07:00AM
Nov 6, 2023 07:23AM
Nov 6, 2023 07:00AM
Aug 7, 2023 07:01AM
Aug 7, 2023 07:00AM Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
May 8, 2023 07:00AM
May 2, 2023 07:01AM
Feb 23, 2023 08:44AM
Feb 23, 2023 07:00AM
Nov 8, 2022 07:09AM
Nov 8, 2022 07:00AM
Aug 3, 2022 07:00AM Aclaris Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
May 10, 2022 07:08AM
May 10, 2022 07:00AM
Feb 24, 2022 09:20AM
Feb 24, 2022 07:02AM
Feb 24, 2022 07:00AM
Nov 2, 2021 07:00AM
Aug 5, 2021 07:00AM Aclaris Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
May 7, 2021 07:00AM
Feb 25, 2021 07:00AM
Nov 4, 2020 01:38PM
Nov 4, 2020 07:00AM
Aug 7, 2020 07:00AM
May 7, 2020 04:01PM
Feb 25, 2020 04:01PM Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
Feb 19, 2020 05:00PM
Jan 10, 2020 09:27AM
Jan 9, 2020 05:52PM
Nov 7, 2019 04:01PM
Oct 31, 2019 04:01PM
Oct 6, 2019 10:00AM
Sep 10, 2019 07:30PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National General, Mallinckrodt, Oasmia Pharmaceutical, and Aclaris Therapeutics and Encourages Investor
Aug 27, 2019 08:00AM

1,198,742 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All